Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $152000.0.

  • Tarsus Pharmaceuticals' Amortization of Deferred Charges rose 1782.95% to $152000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $575000.0, marking a year-over-year increase of 2637.36%. This contributed to the annual value of $482000.0 for FY2024, which is 2519.48% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Amortization of Deferred Charges stood at $152000.0, which was up 1782.95% from $146000.0 recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Amortization of Deferred Charges peaked at $152000.0 during Q3 2025, and registered a low of $28000.0 during Q2 2023.
  • Over the past 4 years, Tarsus Pharmaceuticals' median Amortization of Deferred Charges value was $101000.0 (recorded in 2024), while the average stood at $92400.0.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first plummeted by 2826.09% in 2023, then skyrocketed by 29090.91% in 2024.
  • Tarsus Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $78000.0 in 2022, then skyrocketed by 42.31% to $111000.0 in 2023, then grew by 24.32% to $138000.0 in 2024, then grew by 10.14% to $152000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $152000.0 for Q3 2025, versus $146000.0 for Q2 2025 and $139000.0 for Q1 2025.